Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2019 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.

Related

Vinge advises Oral Care in connection with the acquisition of Dutch dental care provider De Tandartsengroep (DTG)

DTG operates 31 clinics and 8 dental laboratories in the Netherlands. Oral Care is a portfolio company of Axcel VI and operates a network of dental clinics in Sweden, Norway and the Netherlands. To support this expansion, Axcel VII is joining Axcel VI as a shareholder in Oral Care.
February 19, 2025

Vinge advises Gotlandsbolaget in connection with off-take agreement regarding biogas

Vinge has advised Rederiaktiebolaget Gotland (Gotlandsbolaget) in connection with the entry into of a strategic off-take agreement, which secures the long-term supply of biogas for the Gotland ferry service traffic.
February 17, 2025

Vinge advises HAKI Safety AB in connection with the acquisition of Trimtec

Trimtec is a Swedish distributor of high-tech precision equipment.
February 14, 2025